MARKSANS vs RELIANCE
Head-to-head DCF comparison · MARKSANS PHARMA LIMITED vs Reliance Industries
Model Favors
MARKSANS shows a larger model margin of safety
Leads on 3 of 4model metrics · not investment advice
MARKSANS
MARKSANS PHARMA LIMITED
Pharma
₹193
UndervaluedRELIANCE
Reliance Industries
Oil & Gas
₹1,343
Fairly Valued| Metric | MARKSANS | RELIANCE |
|---|---|---|
| Verdict | Undervalued | Fairly Valued |
| YieldIQ Score | 70/100 | 30/100 |
| Fair Value | ₹300 | ₹1,266 |
| Current Price | ₹193 | ₹1,343 |
| Margin of Safety | +55.2% | -5.8% |
| Moat | Wide | Moderate |
| Piotroski F-Score | 5/9 | 6/9 |
| ROE | — | 6.9% |
| Debt / Equity | 0.12 | — |
| EV / EBITDA | 15.9× | 14.3× |
| Market Cap | ₹8,757 Cr | ₹18.18 Lakh Cr |
Run the full interactive analysis
DCF sliders, sensitivity tables, peer screens, watchlists — free to start.
Sign up free →Model estimates using publicly available data. Not investment advice. YieldIQ is not registered with SEBI as an investment adviser or research analyst.